...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cancer >HGF, sIL-6R and TGF-β1 Play a Significant Role in the Progression of Multiple Myeloma
【24h】

HGF, sIL-6R and TGF-β1 Play a Significant Role in the Progression of Multiple Myeloma

机译：HGF，sIL-6R和TGF-β1在多发性骨髓瘤的进展中起重要作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background. In the last few years, it has been widely reported that proinflammatory and angiogenic cytokines are important for the development and progression of multiple myeloma (MM). Objectives. To further validate and acquire more insight into this view we decided to check whether plasma levels of certain cytokines and their soluble receptors differ between MM patients and healthy subjects. Patients and Methods. The study was conducted in 76 MM patients aged 22 to 77 years (60±10 years) and 35 healthy controls aged 20 to 63 years (33±10 years). Plasma levels of interleukin-6 (IL-6), b-fibroblast growth factor (b-FGF), hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF) and transforming growth factor-β1 (TGF-β1), as well as soluble receptors for IL-6 (sIL-6R) and VEGF (sVEGF-R2) were measured using enzyme-linked immunosorbent assay (ELISA). Results. Significantly higher plasma levels of IL-6 (13.65±42.61 vs. 1.04±1.12 pg/ml, p=0.006), HGF (2174±2714 vs. 648±130 pg/ml, pvs. 2.54±5.38 pg/ml, pvs. 25.3±6.4 ng/ml, p=0.003) were observed in MM patients vs. healthy controls, respectively. Plasma sVEGF-R2 was significantly lower in MM patients than in controls (7518±2119 vs. 8725±1281 pg/ml, respectively; p1 in plasma. Conclusions. Plasma levels of HGF, b-FGF, IL-6 and sIL-6R in MM patients were higher ??when compared to the control group. Antineoplastic therapy leads to a time-dependent decrease in plasma levels of sIL-6R, and TGF-β1 in MM patients. Blood plasma level of HGF is an optimal measure to differentiate patients in whom disease is progressing versus patients who respond to therapy.
机译：背景。在最近几年中，广泛报道促炎性和血管生成性细胞因子对多发性骨髓瘤（MM）的发生和发展很重要。目标。为了进一步验证并获得对该视图的更多见解，我们决定检查MM患者和健康受试者之间某些细胞因子及其可溶性受体的血浆水平是否存在差异。患者和方法。这项研究是针对年龄在22至77岁（60±10岁）的76位MM患者和年龄在20至63岁（33±10岁）的35位健康对照进行的。血浆白细胞介素6（IL-6），b-成纤维细胞生长因子（b-FGF），肝细胞生长因子（HGF），血管内皮生长因子（VEGF）和转化生长因子-β 1 （TGF-β 1 ）以及IL-6（sIL-6R）和VEGF（sVEGF-R2）的可溶性受体使用酶联免疫吸附测定（ELISA）进行了测量。结果。 IL-6，HGF（2174±2714 vs. 648±130 pg / ml，pvs。2.54±5.38 pg / ml，pvs）的血浆水平显着升高（13.65±42.61 vs. 1.04±1.12 pg / ml，p = 0.006）在MM患者与健康对照组中分别观察到25.3±6.4 ng / ml，p = 0.003）。结论：MM患者血浆中sVEGF-R2水平显着低于对照组（分别为7518±2119 vs. 8725±1281 pg / ml;血浆中为p1 。）结论：血浆中HGF，b-FGF，IL-6水平MM患者的sIL-6R和sIL-6R高于对照组，抗肿瘤治疗导致MM患者的sIL-6R和TGF-β 1 血浆水平随时间下降。HGF的血浆水平是区分疾病进展患者和对治疗有反应的患者的最佳方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号